Nils Erik Gilhus
Haukeland University Hospital
338 Papers
1.9K Citations
Nils Erik Gilhus is an academic researcher from Haukeland University Hospital. The author has contributed to research in topics: Myasthenia gravis & Medicine. The author has an hindex of 57, co-authored 316 publications. Previous affiliations of Nils Erik Gilhus include University of Bergen.
Chat about Author
Papers
Traumatic spinal cord injuries - incidence, mechanisms and course
TL;DR: There are large geographical differences in reported incidence, prevalence and lethality, mainly attributable to differences in definition, inclusion, classification and patient identification procedures in the various studies, together with geographical and cultural differences and differences in prehospital and hospital treatment.
Seronegative myasthenia gravis: disease severity and prognosis.
TL;DR: It is shown that the presence of AChR antibodies in MG patients correlates with a more severe MG, and with proper treatment, especially early thymectomy for seropositive MG, the outcome and long‐term prognosis is good in patients with and without A ChR antibodies.
93
Autoantibodies in Thymoma-Associated Myasthenia Gravis With Myositis or Neuromyotonia
Åse Mygland,Angela Vincent,John Newsom-Davis,Henry J. Kaminski,Francesco Zorzato,Mark A. Agius,Nils Erik Gilhus,Johan A. Aarli +7 more
TL;DR: The results appear to distinguish partially between 3 groups of patients with thymoma-associated MG: the first with RyR antibodies and myositis or myocarditis, the second with NMT withoutRyR antibodies, and the third without RyR antibody, myositIS, or NMT.
92
Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis.
TL;DR: The presence of circulating RyR antibodies seems to be associated with a severe form of thymoma associated myasthenia gravis, which is a calcium release channel involved in the mechanism of excitation-contraction coupling in striations.
88
Serum Levels of Matrix Metalloproteinases: Implications in Clinical Neurology
TL;DR: Serological clinical aspects of MMPs in neurological disorders and healthy controls include serum MMP-2, -3, and -9 levels, which correlates with larger infarct volume, stroke severity, and worse functional outcome, and serum M MP-3 is significantly lower than in several other neurological disordersand healthy controls.